In This Article:
-
Revvvi Forge Net Revenue: $20 million in the first full quarter of the launch.
-
Nick Timbo Net Revenue: $13.6 million from the first two months of the joint launch with Insight.
-
Total Combined Net Sales: $34 million from Revvvi Forge and Nick Timbo.
-
Cash and Equivalents: $602.1 million as of March 31st.
-
Collaboration Loss: $200,000 share of the net commercial loss for Nick Timbo.
-
Managed Care Coverage: 72% of all managed care lives have formal coverage policies for Revvvi Forge.
-
Infusions Administered: More than 1,250 infusions of Nick Timbo administered year-to-date.
-
Top Accounts Ordering Nick Timbo: Approximately 95% of top accounts and more than 70% of all bone marrow transplant centers have ordered.
Release Date: May 05, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) reported strong financial performance with $20 million in net revenue from Revvvi Forge and $13.6 million from Nick Timbo in the first quarter of 2025.
-
The company has a robust pipeline with ongoing clinical trials, including the initiation of the Evolve II trial for Revvvi Forge, targeting a high unmet medical need in AML patients.
-
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) is well-funded with $602.1 million in cash and equivalents, supporting its strategic initiatives and potential market expansions.
-
The company has achieved significant milestones, including the submission of a supplemental new drug application (SNDA) for Revvvi Forge, seeking priority review for the treatment of relapse or refractory mutant NPM1 AML.
-
Strong market access and formulary coverage for Revvvi Forge, with approximately 72% of managed care lives covered, facilitating quick patient access to the medication.
Negative Points
-
The company faces challenges in accurately estimating the total addressable market for its products, as the actual patient population may differ from initial projections.
-
There is limited data on the long-term duration of therapy and refill dynamics for Revvvi Forge, making it difficult to predict future revenue streams accurately.
-
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) is still in the early stages of collecting real-world evidence for its products, which may impact the ability to provide detailed insights into patient outcomes and treatment patterns.
-
The company has not yet provided specific details on the powering of its Evolve II trial, which could affect investor confidence in the trial's potential success.
-
Reimbursement for post-transplant use of Revvvi Forge remains uncertain, which could impact the drug's adoption and revenue potential in this setting.